{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:42:06Z","timestamp":1757706126114,"version":"3.40.2"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID 04138 - Instituto de Investiga\u00e7\u00e3o do Medicamento"],"award-info":[{"award-number":["UID 04138 - Instituto de Investiga\u00e7\u00e3o do Medicamento"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Ther Perspect"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40267-025-01145-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T14:28:42Z","timestamp":1740752922000},"page":"111-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulatory and clinical aspects in biosimilar medicines: comparability, extrapolation, interchangeability, and safety"],"prefix":"10.1007","volume":"41","author":[{"given":"Miguel C.","family":"Raposo","sequence":"first","affiliation":[]},{"given":"Cl\u00e1udia","family":"Feiteira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-7861","authenticated-orcid":false,"given":"Maria H. L.","family":"Ribeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"1145_CR1","unstructured":"European Commission. What You Need to Know About Biosimilar Medicines\u2014Information for Patients. 2016. https:\/\/www.infarmed.pt\/documents\/15786\/1410451\/O+que+preciso+saber+sobre+medicamentos+biossimilares\/4c384240-ee3e-4978-889d-b1b47b31ffe1."},{"key":"1145_CR2","unstructured":"Pombal R. Pharmacovigilance Bulletin\u2014Biosimilar Medicines. 2019. https:\/\/www.infarmed.pt\/documents\/15786\/3020432\/Boletim%2Bde%2BFarmacovigil%FF%FFncia%2C%2BVolume%2B23%2C%2Bn%FF%FF3%2C%2Bmar%FF%FFo%2Bde%2B2019\/d210e2d8-74a6-4596-ab87-286ecca20b7c."},{"key":"1145_CR3","unstructured":"European Medicines Agency. Biosimilar Medicines: Overview 2023. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview."},{"key":"1145_CR4","unstructured":"https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"1145_CR5","unstructured":"Biosimilar Medicines in the EU. Prepared jointly by the European Medicines Agency and the European Commission. 2019. https:\/\/www.ema.europa.eu\/pt\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_pt.pdf."},{"key":"1145_CR6","unstructured":"Catarina Silva A, Lobo SJ. Biological medicines\u2014examples approved in Portugal. 2020. https:\/\/actafarmaceuticaportuguesa.com\/index.php\/afp\/article\/view\/221."},{"key":"1145_CR7","unstructured":"Zulmira Gomes de Sousa Brand\u00e3o C, Natal de Souza J. Biopharmaceuticals: from research to market\u2014a literature review. Health Sci Act. 2015."},{"key":"1145_CR8","unstructured":"CHMP. Guideline on similar biological medicinal products. 2014."},{"issue":"3","key":"1145_CR9","first-page":"272","volume":"30\u201327","author":"RM Nogueira","year":"2021","unstructured":"Nogueira RM, Cunha JC, Lima A, Fernandes D, Guedes C, Duarte A. Biosimilars: are they really so similar? Med Interna (Bucur). 2021;30\u201327(3):272\u20134.","journal-title":"Med Interna (Bucur)."},{"key":"1145_CR10","unstructured":"FDA. Biosimilars\u2014basics for patients. 2024. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilars-basics-patients."},{"key":"1145_CR11","unstructured":"Infarmed. Infomed. 2024. https:\/\/extranet.infarmed.pt\/INFOMED-fo\/."},{"key":"1145_CR12","doi-asserted-by":"crossref","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford, England). 2017;56:iv14\u201329.","DOI":"10.1093\/rheumatology\/kex278"},{"key":"1145_CR13","unstructured":"Ferreira J. Biosimilar medicines\u2014market characterization 2010\u20132020. 2010. https:\/\/www.infarmed.pt\/documents\/15786\/2219894\/Medicamentos+Biossimilares+2010+2020\/ccd0b15f-a36b-b97b-6143-9de16e7af79d."},{"issue":"139","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2020.07.037","volume":"1","author":"K H\u00fcbel","year":"2020","unstructured":"H\u00fcbel K, Kron F, Lux MP. Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer. 2020;1(139):10\u20139.","journal-title":"Eur J Cancer"},{"key":"1145_CR15","unstructured":"Aitken M. Biosimilars in the United States 2023\u20132027. 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027."},{"issue":"7","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/1995-7645.285827","volume":"13","author":"M Thiruvengadam","year":"2020","unstructured":"Thiruvengadam M, Venkidasamy B, Chung IM, Thirupathi P, Subramanian U. Biosimilars: a novel perspective in diabetes therapy. Asian Pac J Trop Med. 2020;13(7):288.","journal-title":"Asian Pac J Trop Med"},{"key":"1145_CR17","unstructured":"Jornal de Noticias. Infarmed Monitors Daily Transactions of Diabetes Drugs. 2023. https:\/\/www.jn.pt\/5612048956\/infarmed-monitoriza-ao-dia-transacoes-de-farmacos-para-a-diabetes\/."},{"key":"1145_CR18","doi-asserted-by":"crossref","unstructured":"Rahalkar H, Cetintas HC, Salek S. Quality, non-clinical and clinical considerations for biosimilar monoclonal antibody development: EU, WHO, USA, Canada, and BRICS-TM regulatory guidelines. Vol. 9, Frontiers in Pharmacology. Frontiers Media S.A. 2018.","DOI":"10.3389\/fphar.2018.01079"},{"key":"1145_CR19","unstructured":"European Medicines Agency. ICH Topic Q 5 E comparability of biotechnological\/biological products. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-e-comparability-biotechnologicalbiological-products-step-5_en.pdf."},{"key":"1145_CR20","unstructured":"FDA. Biosimilars. 2024. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars."},{"key":"1145_CR21","unstructured":"NPMA. 2024. https:\/\/english.nmpa.gov.cn\/."},{"key":"1145_CR22","unstructured":"PMDA. 2024.(https:\/\/www.pmda.go.jp\/english\/."},{"key":"1145_CR23","unstructured":"ANVISA. 2024. https:\/\/www.gov.br\/anvisa\/pt-br."},{"key":"1145_CR24","unstructured":"Health Canada. 2024. https:\/\/www.canada.ca\/en\/health-canada.html."},{"key":"1145_CR25","unstructured":"European Medicines Agency. ICH Topic Q 6 B specifications: test procedures and acceptance criteria for biotechnological\/biological products. 1999 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-6-b-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products-step-5_en.pdf."},{"key":"1145_CR26","unstructured":"CHMP. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (Revision 1). 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-quality-issues-revision-1_en.pdf."},{"key":"1145_CR27","doi-asserted-by":"crossref","unstructured":"Mascarenhas-Melo F, Diaz M, Gon\u00e7alves MBS, Vieira P, Bell V, Viana S, et al. An overview of biosimilars\u2014development, quality, regulatory issues, and management in healthcare. Pharmaceuticals. Multidisciplinary Digital Publishing Institute (MDPI). 2024; 17.","DOI":"10.3390\/ph17020235"},{"key":"1145_CR28","unstructured":"ICH | Quality Guidelines. 2024. https:\/\/www.ich.org\/page\/quality-guidelines."},{"key":"1145_CR29","unstructured":"ICH Q6B. 1999."},{"key":"1145_CR30","unstructured":"ICH Q5C. 1995."},{"key":"1145_CR31","unstructured":"EMA\u2014Homepage. 2024. https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"1145_CR32","unstructured":"CHMP. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf."},{"key":"1145_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40259-024-00655-4","volume":"38","author":"HP Cohen","year":"2024","unstructured":"Cohen HP, Bodenmueller W. Additional data in expanded patient populations and new indications support the practice of biosimilar-to-biosimilar switching. BioDrugs. 2024;38:331\u20139.","journal-title":"BioDrugs"},{"issue":"10","key":"1145_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18(10): e0292231.","journal-title":"PLoS ONE"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108:734\u201355.","journal-title":"Clin Pharmacol Ther"},{"key":"1145_CR36","unstructured":"CHMP. Product-Specific Biosimilar Guidelines. 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-biosimilar."},{"issue":"4","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463\u201378.","journal-title":"Drugs"},{"key":"1145_CR38","unstructured":"Fernandes JP, Gon\u00e7alves J. Safety and clinical efficacy in biosimilar substitution: critical review of the literature. Rev Port Farmacoter 2015. p. 7."},{"issue":"2","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40259-017-0210-0","volume":"31","author":"P Kurki","year":"2017","unstructured":"Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83\u201391.","journal-title":"BioDrugs"},{"key":"1145_CR40","unstructured":"EMA\/627319\/2022. HMA\u2014Heads of Medicines Agencies\u2014Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf."},{"key":"1145_CR41","unstructured":"Biosimilars in the EU\u2014Information guide for healthcare professionals. European Medicines Agency and the European Commission. 2019 https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf."},{"key":"1145_CR42","unstructured":"EMA. Statement on the Scientific Rationale Supporting Interchangeability of Biosimilar Medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf."},{"issue":"2","key":"1145_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2021.1889511","volume":"22","author":"AS Rathore","year":"2022","unstructured":"Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther. 2022;22(2):133\u201348.","journal-title":"Expert Opin Biol Ther"},{"key":"1145_CR44","doi-asserted-by":"crossref","unstructured":"Druedahl LC, Ka \u00a8lvemark Sporrong S, Minssen T, Hoogland H, De Bruin ML, van de Weert M, et al. Interchangeability of biosimilars: a study of expert views and visions regarding the science and substitution. PLoS One. 2022;17(1):e0262537","DOI":"10.1371\/journal.pone.0262537"},{"key":"1145_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.11.002","volume":"126","author":"C Scavone","year":"2017","unstructured":"Scavone C, Rafaniello C, Berrino L, Rossi F, Capuano A. Strengths, weaknesses and future challenges of biosimilars\u2019 development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacol Res. 2017;126:138\u201342.","journal-title":"Pharmacol Res"},{"key":"1145_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40259-021-00478-7","volume":"35","author":"LC Druedahl","year":"2021","unstructured":"Druedahl LC, K\u00e4lvemark Sporrong S, van de Weert M, et al. Evolving biosimilar clinical requirements: a qualitative interview study with industry experts and European national medicines agency regulators. BioDrugs. 2021;35:351\u201361.","journal-title":"BioDrugs"},{"key":"1145_CR47","unstructured":"Biosimilar and Interchangeable Biologics: More Treatment Choices. U.S. Food and Drug Administration. 2023. https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices."},{"key":"1145_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40259-024-00649-2","volume":"38","author":"N Mohd Sani","year":"2024","unstructured":"Mohd Sani N, Aziz Z, Kamarulzaman A. Use of biosimilars: a systematic review of published position statements and recommendations from health organisations and societies. BioDrugs. 2024;38:405\u201323.","journal-title":"BioDrugs"},{"key":"1145_CR49","unstructured":"FDA updates guidance on interchangeability. 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-guidance-interchangeability."},{"key":"1145_CR50","unstructured":"Things to Know About Biosimilars and Interchangeable Biosimilars. 2024. https:\/\/www.fda.gov\/drugs\/things-know-about\/9-things-know-about-biosimilars-and-interchangeable-biosimilars."},{"issue":"1","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-021-00508-4","volume":"36","author":"RW Meijboom","year":"2022","unstructured":"Meijboom RW, Gardarsdottir H, Egberts TCG, Giezen TJ. Patients retransitioning from biosimilar TNF\u03b1 inhibitor to the corresponding originator after initial transitioning to the biosimilar: a systematic review. BioDrugs. 2022;36(1):27\u201339.","journal-title":"BioDrugs"},{"issue":"5","key":"1145_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2024.2357381","volume":"24","author":"A Spini","year":"2024","unstructured":"Spini A, Pellegrini G, Ingrasciotta Y, L\u2019Abbate L, Bellitto C, Carollo M, et al. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network. Expert Opin Biol Ther. 2024;24(5):399\u2013409.","journal-title":"Expert Opin Biol Ther"},{"key":"1145_CR53","unstructured":"EMA. Committee for medicinal products for human use, Summary of positive opinion for Zarzio. 2008. http:\/\/www.emea.europa.eu."},{"key":"1145_CR54","unstructured":"CHMP. Summary of drug characteristics\u2014Zarzio. 2008."},{"key":"1145_CR55","unstructured":"EMA. CHMP Public assessment report for Zarzio. 2008. p. 45."},{"key":"1145_CR56","unstructured":"CHMP. Annex-guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-guidance-similar-medicinal-products-containing_en. 2006."},{"key":"1145_CR57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40259-019-00373-2","volume":"33","author":"P Gascon","year":"2019","unstructured":"Gascon P, Krendyukov A, Mathieson N, Natek M, Aapro M. Extrapolation in practice: lessons from 10 years with biosimilar filgrastim. BioDrugs. 2019;33:635\u201345.","journal-title":"BioDrugs"},{"key":"1145_CR58","doi-asserted-by":"crossref","unstructured":"Islami MM, Khan MA, Aseeri MA, Alshamrani MA, Alnatsheh A, Alamoudi S, et al. Comparison of biosimilar filgrastim with innovator filgrastim for peripheral blood stem cells mobilization, collection of CD34+ stem cells, and engraftment in patients undergoing autologous and allogeneic stem cell transplantation: a single-center experience. Ann Transplant. 2023;28.","DOI":"10.12659\/AOT.938585"},{"key":"1145_CR59","unstructured":"CHMP. Uzpruvo, INN\u2014ustekinumab 2024. www.ema.europa.eu\/contact."},{"key":"1145_CR60","unstructured":"Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. 2012. www.ema.europa.eu."},{"key":"1145_CR61","unstructured":"CHMP. Summary of drug characteristics\u2014Humulin Regular. 2015."},{"key":"1145_CR62","unstructured":"CHMP. Committee for Medicinal products for Human Use (CHMP) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. www.ema.europa.eu\/contact."},{"key":"1145_CR63","unstructured":"CHMP. Solumarv, INN-insulin human\u2014Q&A 2024. www.ema.europa.eu\/contact."},{"key":"1145_CR64","unstructured":"CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment report for Solumarv. 2024. www.ema.europa.eu\/contact."}],"container-title":["Drugs & Therapy Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-025-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40267-025-01145-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-025-01145-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T02:52:42Z","timestamp":1742611962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40267-025-01145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s40267-025-01145-5","relation":{},"ISSN":["1172-0360","1179-1977"],"issn-type":[{"type":"print","value":"1172-0360"},{"type":"electronic","value":"1179-1977"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"6 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by FCT\u2014FOUNDATION FOR SCIENCE AND TECHNOLOGY, I.P., through National Funds, under the project UID 04138 - Instituto de Investiga\u00e7\u00e3o do Medicamento.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no conflicts of interest regarding the publication of the present manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to this article and are responsible for its content. All authors read and approved the final version of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}